10-671,253

```
=> d his

     (FILE 'MEDLINE, CANCERLIT, AGRICOLA, CAPLUS, SCISEARCH' ENTERED AT
     14:52:30 ON 22 JUL 2005)
                DEL HIS
L1          71473 S POTASSIUM CHANNEL
L2           2511 S L1 AND (KV1.5 OR KV2.1 OR KV2.1/9.3 OR KV1.2 OR KV3.1)
L3         100323 S ADENOVIR?
L4             39 S L2 AND L3
L5             23 S L4 AND PY<=2002
L6              9 DUP REM L5 (14 DUPLICATES REMOVED)
L7              9 FOCUS L6 1-
                  E  ARCHER STEPHEN?/AU
L8            180 S E1
                  E MICHELAKIS EVAN?/AU
L9             14 S E4
L10            53 S E5
L11           194 S L8 OR L9 OR L10
L12            23 S L11 AND L2
L13            15 DUP REM L12 (8 DUPLICATES REMOVED)
L14             6 S L13 AND L3

=>

=> d an ti so au ab pi l14 5

L14  ANSWER 5 OF 6  CAPLUS  COPYRIGHT 2005 ACS on STN
AN   2004:533965  CAPLUS
DN   141:66262
TI   Adenoviral expression vectors for therapeutic expression of
     potassium channel genes in the treatment of vascular
     disease
SO   U.S. Pat. Appl. Publ., 63 pp.
     CODEN: USXXCO
IN   Archer, Stephen L.; Michelakis, Evangelos D.
AB   A method of treating vascular diseases including hypoxic pulmonary
     hypertension by increasing the levels of potassium
     channels in the affected tissue is described.  The method involves
     using adenoviral vectors expressing genes for potassium
     channels.  The loss of the Kv1.5 voltage-gated
     potassium channel is typical of chronic hypoxic
     hypertension.  Construction of a human adenovirus 5 expression
     vector for a cDNA for the human Kv1.5
     potassium channel using the com. pAdTrack system is
     demonstrated.  A non-specific promoter from human cytomegalovirus and the
     smooth muscle-specific SM22a promoter were constructed.
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     --------------      ----   --------    --------------------   --------
PI   US 2004127447        A1    20040701    US 2003-671253         20030925
```